Augustine Therapeutics

Augustine Therapeutics

Foundation date

12/03/2019

Sector

#Biotechnology - Therapeutics

Subsector

• #Therapeutics - Drug delivery
• #Therapeutics - Small molecules
• #Pharma - Molecular diagnostics

Therapeutic areas

• #Digestive system
• #Diseases of the nervous system

Augustine Therapeutics focuses on the development of new medicines to treat severe debilitating diseases with high unmet need, in particular Charcot-Marie-Tooth disease (CMT) as well as other peripheral neuropathies. Augustine Therapeutics completed a seed financing round of €4.2 million in December 2019 with the support of VIB, V-Bio Ventures and PMV joined by Advent France Biotechnology and the Gemma Frisius Fund. Augustine Therapeutics is a drug discovery company building a portfolio of first-in-class drugs rooted in the ground-breaking research on neurodegenerative disorders of Prof. Ludo Van Den Bosch, Prof. Joris De Wit and Prof. Bart De Strooper at VIB.